12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

S*BIO, Verastem preclinical data

In a mouse model of breast cancer, 25 mg/kg oral VS-5584 significantly reduced the percent of cancer stem cells in extracted tumors vs. untreated controls. In a mouse model of docetaxel-resistant triple-negative breast cancer...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >